Contemporary Pediatrics week in review: Tool to aid in autism diagnosis, increased RSV activity, and more
Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
Contemporary Pediatrics week in review: Tool to aid in autism diagnosis, increased RSV activity, and more | Image Credit: Contemporary Pediatrics
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from last week (Monday, September 4 to Friday, September 8, 2023) and click each link to read and watch anything you may have missed.
1.) FDA-cleared tool could assist in diagnosing autism
The EarliPoint Evaluation has demonstrated positive phase 3 trial results, aiding in autism diagnosis and assessment in children aged 16 to 30 months. Warren Jones, PhD, chief scientific officer and cofounder of EarliTec Diagnostics, Inc., discusses the eye-tracking tool, how it is currently being used, and what could be in store for the future.
Click here to watch the full interview.
2.) CDC issues health advisory alert after increases in RSV activity
Due to increased RSV activity observed in Southeastern regions of the United States, the Centers for Disease Control and Prevention (CDC) has issued an official Health Alert Network Health Advisory. The CDC recommends that clinicians prepare to implement recently FDA-approved prevention methods.
Click here for the full article.
3.) GARDASIL 9 shows positive long-term results against HPV-related cancers
The effects of GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in patients aged 9 to 15 years has indicated efficacy, according to a recent long-term follow-up study.
Click here for the full article.
4.) Pediatric T1D management adherence system evaluated in study
Numerous tools, technology platforms, and interventions have been developed to help teens with the difficult emotional and physical weight of managing the disease.
Click here for the full article.
5.) Discussing VP-102 to treat molluscum contagiosum in patients 2 years and up
In this Contemporary Pediatrics interview, Bernard A. Cohen, MD, discusses VP-102, approved by the FDA on July 22, 2023, to treat molluscum contagiosum in pediatric patients 2 years and up.
The Role of the Healthcare Provider Community in Increasing Public Awareness of RSV in All Infants
April 2nd 2022Scott Kober sits down with Dr. Joseph Domachowske, Professor of Pediatrics, Professor of Microbiology and Immunology, and Director of the Global Maternal-Child and Pediatric Health Program at the SUNY Upstate Medical University.
